What is the recommended peri‑operative (neoadjuvant and adjuvant) modified FOLFOX6 (mFOLFOX6) chemotherapy regimen for adenocarcinoma of the gastro‑esophageal junction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Perioperative mFOLFOX6 for GE Junction Adenocarcinoma

For locally advanced gastroesophageal junction adenocarcinoma, perioperative FLOT (docetaxel-oxaliplatin-5-fluorouracil) is the current standard of care, not mFOLFOX6, and should be used with durvalumab when available 1.

Current Standard Regimen

The 2026 ESMO guidelines explicitly state that for locally advanced (≥cT2 or cN+, M0) gastroesophageal adenocarcinoma, perioperative FLOT with radical surgery is the standard of care chemotherapy-based approach 1. The addition of durvalumab to FLOT (D-FLOT) followed by durvalumab maintenance is now the preferred option when available 1.

Why FLOT Over mFOLFOX6

  • FLOT4 trial established FLOT superiority over older regimens (ECF/ECX) with improved overall survival and pathologic complete response rates 2
  • ESOPEC trial demonstrated FLOT's superiority over chemoradiotherapy (CROSS regimen) for overall survival in GEJ adenocarcinoma 2
  • FLOT includes docetaxel, which mFOLFOX6 lacks—this triplet drug combination provides superior efficacy

When mFOLFOX6 May Be Considered

mFOLFOX6 is relegated to a second-line alternative only when patients are unsuitable for FLOT 1. The guidelines specifically state: "Patients unsuitable for both FLOT and CRT may receive an oxaliplatin-fluoropyrimidine doublet" 1.

mFOLFOX6 Dosing (When Used)

Based on research evidence, the standard mFOLFOX6 regimen consists of 3, 4:

  • Oxaliplatin 85 mg/m² IV over 2 hours
  • Leucovorin 400 mg/m² IV over 2 hours
  • 5-FU 400 mg/m² IV bolus
  • 5-FU 2400 mg/m² continuous infusion over 46 hours
  • Administered every 2 weeks

Perioperative Schedule for mFOLFOX6

When mFOLFOX6 is used 3, 5:

  • Preoperative: 3-4 cycles (6-8 weeks)
  • Surgery: 4 weeks after last chemotherapy cycle
  • Postoperative: 2-4 cycles starting 4-8 weeks after surgery

Clinical Outcomes with mFOLFOX6

Research data shows mFOLFOX6 achieves 3, 5:

  • R0 resection rates: 95-100%
  • Pathologic response (≥50% regression): 49-90%
  • Pathologic complete response: 21%
  • 3-year overall survival: 92.3%
  • Feasibility: 92% complete preoperative treatment

Toxicity Profile

Grade 3-4 toxicities with mFOLFOX6 include 3, 5, 4:

  • Neutropenia: 33-34%
  • Neuropathy: 20.5%
  • Neutropenic fever: reported but uncommon
  • Thromboembolism: 7.7%

Modified FLOT Dosing (Preferred Standard)

Recent real-world data demonstrates that dose-modified FLOT maintains efficacy while improving tolerability 6:

  • Fluorouracil 2400 mg/m² over 46-48 hours (reduced from standard 2600 mg/m²)
  • Oxaliplatin 85 mg/m²
  • Docetaxel 40-50 mg/m² (reduced from standard 50 mg/m²)
  • Every 2 weeks

This modified FLOT achieved 88% R0 resection, 16% pCR, and 3-year OS of 75.3% with manageable toxicity 6.

Immunotherapy Integration

The treatment landscape has shifted with immunotherapy 1, 2:

  • MATTERHORN trial demonstrated that durvalumab plus perioperative FLOT significantly improved event-free survival, establishing D-FLOT as the new emerging global standard 7
  • This represents the most recent advancement and should be prioritized when available

Critical Caveats

  • mFOLFOX6 lacks docetaxel, which is a key component of the superior FLOT regimen
  • Use mFOLFOX6 only if patient has contraindications to docetaxel or FLOT is unavailable
  • For patients with PD-L1-positive tumors unsuitable for FLOT, consider preoperative chemoradiotherapy followed by surgery and adjuvant nivolumab (if R0 resection with residual disease) 1
  • Do not use mFOLFOX6 as first choice—it represents a compromise when standard therapy cannot be delivered

Algorithm for Treatment Selection

  1. First choice: Perioperative FLOT + durvalumab (D-FLOT) if available 1
  2. Second choice: Perioperative FLOT alone if durvalumab unavailable 1
  3. Third choice: Preoperative chemoradiotherapy + surgery + adjuvant nivolumab (if PD-L1+ and unsuitable for FLOT) 1
  4. Fourth choice: Oxaliplatin-fluoropyrimidine doublet (mFOLFOX6) if unsuitable for both FLOT and CRT 1

The evidence is clear: FLOT-based regimens are superior to mFOLFOX6 for GE junction adenocarcinoma, and mFOLFOX6 should only be used when FLOT cannot be administered.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.